Stocks Health care CRL
NYSE · Health careCharles River Laboratories International, Inc. (CRL)
Charles River Laboratories International, Inc. brought in $4B of revenue over the twelve months to September 26, 2026, down 1.2% from a year earlier. Net income was $40.2M, a net margin of 1.0%. Operating cash flow minus capital spending left $518.5M of free cash flow in fiscal 2025. At September 26, 2026 it held $200.4M in cash against $2.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Charles River Laboratories International, Inc.
- Net worth
- Charles River Laboratories International, Inc. has a market value (market cap) of $16.9B at the latest share price, and shareholders' equity of $3.2B on its balance sheet at September 26, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $4B (-0.9% year on year), with a net loss of $144.3M. Over the 12 months to September 26, 2026: revenue $4B, net income $40.2M.
- Cash flow
- In fiscal 2025 operations brought in $737.6M of cash; after $219.2M of capital spending, free cash flow was $518.5M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 26, 2026. Open on SEC EDGAR
- Next earnings report
- Charles River Laboratories International, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Charles River Laboratories International, Inc. does
Charles River Laboratories International, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NYSE under the ticker CRL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4B | -$144.3M | -$2.91 | $518.5M |
| 2024 | $4B | $22.2M | $0.20 | $501.6M |
| 2023 | $4.1B | $474.6M | $9.22 | $365.4M |
| 2022 | $4B | $486.2M | $9.48 | $294.9M |
| 2021 | $3.5B | $391M | $7.60 | $532M |
| 2020 | $2.9B | $364.3M | $7.20 | $380M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CRL ranks in Health care
Latest SEC filings
What Charles River Laboratories International, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026Quarterly report 10-Q · period to September 26, 2026Revenue fell 2.2% to $982.7M versus the same quarter last year; diluted EPS $6.86 versus $1.10.
- November 4, 2026
- September 24, 2026
- September 8, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 27, 2026Revenue fell 2.7% to $1B versus the same quarter last year; diluted EPS -$0.03 versus $1.06.
- August 5, 2026
What is CRL worth? A DCF from its reported cash flow
Insider trades
What the people running Charles River Laboratories International, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $3K and sold $20.3M worth of shares in the last 90 days. Most of the selling (99%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 6, 2026 | Knell Michael GunnarSVP, Finance and CAO | Shares withheld for tax | 649 | $203.1K |
| October 22, 2026 | Foster James CDirector | Exercised options | 24,042 | $5.9M |
| October 22, 2026 | Foster James CDirector | Soldpre-planned (10b5-1) | 24,042 | $8.4M |
| October 21, 2026 | Parisotto Shannon MCEVP, Disc & Safety Assessment | Exercised options | 2,156 | $526.9K |
| October 21, 2026 | Parisotto Shannon MCEVP, Disc & Safety Assessment | Soldpre-planned (10b5-1) | 2,156 | $742.5K |
| October 5, 2026 | Parisotto Shannon MCEVP, Disc & Safety Assessment | Exercised options | 981 | $204.5K |
| October 5, 2026 | Parisotto Shannon MCEVP, Disc & Safety Assessment | Soldpre-planned (10b5-1) | 981 | $302.6K |
| September 30, 2026 | Coleman GlennEVP & Chief Financial Officer | Bought | 10 | $3K |
Who owns CRL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 10.2% | September 8, 2026 |
| Vanguard Capital Management13G, passive | 7.38% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 569 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 4,239,752 | +783,508 |
| BlackRock, Inc. | 3,798,560 | -60,540 |
| Vanguard Capital Management LLC | 3,149,288 | -52,916 |
| Invesco Ltd. | 2,984,785 | +587,533 |
| Harris Associates L P | 2,241,144 | +87,848 |
| Vanguard Portfolio Management LLC | 2,210,979 | -83,691 |
| Allspring Global Investments Holdings, LLC | 1,905,247 | -88,069 |
| State Street Corp | 1,864,284 | -9,334 |
| Dimensional Fund Advisors LP | 1,648,450 | -4,034 |
| Ariel Investments, LLC | 1,506,185 | +62,002 |
| Geode Capital Management, LLC | 1,305,738 | +44 |
| Wellington Management Group Llp | 1,288,463 | -340,938 |
| Citadel Advisors LLC | 1,193,601 | -18,551 |
| Bank of America Corp | 1,172,586 | +37,559 |
| Earnest Partners LLC | 1,120,011 | +148,645 |
| Ameriprise Financial Inc | 881,189 | -228,198 |
| Neuberger Berman Group LLC | 862,704 | -11,674 |
| Sei Investments Co | 813,530 | +56,401 |
| Morgan Stanley | 800,487 | -25,181 |
| Clearbridge Investments, LLC | 781,276 | +148,652 |
Insiders
18 insiders reported holding 299,417 shares in total, about $105.8M at the last price.
| Holder | Shares |
|---|---|
| Girshick BirgitChief Executive Officer, Director | 79,28843,803 held indirectly |
| Foster James CDirector | 41,59610,000 held indirectly |
| LaPlume Joseph WEVP, Corp Strategy & Develop | 31,041 |
| Creamer Victoria LEVP & Chief People Officer | 30,051 |
| Coleman GlennEVP & Chief Financial Officer | 27,762 |
| Mackay MartinDirector | 17,137 |
| Parisotto Shannon MCEVP, Disc & Safety Assessment | 14,4879,680 held indirectly |
| Knell Michael GunnarSVP, Finance and CAO | 11,203 |
| Mintz MarkEVP, Chief Information Officer | 9,546 |
| Llado George Sr.Director | 6,702 |
Questions about CRL
What does Charles River Laboratories International, Inc. do?
Charles River Laboratories International, Inc. is a company in the Health care sector, listed on NYSE as CRL. Its shares trade on NYSE under the ticker CRL.
What is Charles River Laboratories International, Inc.'s net worth?
Charles River Laboratories International, Inc. has a market value (market cap) of $16.9B at the latest share price, and shareholders' equity of $3.2B on its balance sheet at September 26, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Charles River Laboratories International, Inc. profitable?
Yes. Over the twelve months to September 26, 2026 it reported net income of $40.2M on revenue of $4B, a net margin of 1.0%.
How much revenue does Charles River Laboratories International, Inc. make?
Over the twelve months to September 26, 2026 Charles River Laboratories International, Inc. reported revenue of $4B. That is 1.2% less than a year earlier.
When did Charles River Laboratories International, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 26, 2026. Its newest filing of any kind is the investor disclosure from November 9, 2026.
When is Charles River Laboratories International, Inc.'s next earnings report?
Charles River Laboratories International, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CRL with
Follow CRL
Get an email when Charles River Laboratories International, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Charles River Laboratories International, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.